AI Article Synopsis
- The incidence of HPV-related oropharyngeal cancers has been rising, leading to more focus on treatment options.
- Although patients with these cancers have higher cure rates than those with HPV-negative head and neck cancers, treatment often results in significant side effects.
- Current clinical trials are exploring ways to reduce treatment intensity by adjusting chemotherapy, radiation, and surgery methods, including using new therapies like immunotherapy and innovative biomarker detection for monitoring.
Article Abstract
The incidence of HPV-related oropharyngeal cancers has increased in recent decades. While cure rates exceed those of HPV-negative head and neck cancers, both acute and long-term sequelae of chemotherapy, radiation and surgery have led to clinical investigation into de-escalation of treatment. De-escalation trials have sought to reduce long-term treatment-related morbidity by altering or omitting chemotherapy, reducing radiation, or incorporating less invasive surgical resection through transoral surgery. More recent approaches include the use of novel agents such as immunotherapy in place of cisplatin. With the advent of tumor-tissue-modified HPV DNA detection and monitoring in blood, new strategies incorporating this biomarker are being developed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311653 | PMC |
| http://dx.doi.org/10.3390/cancers16152733 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for -Mutated NSCLC After Complete Resection.
JTO Clin Res Rep
January 2025
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
Introduction: EGFR tyrosine kinase inhibitor (TKI) is the standard adjuvant treatment for patients with stages IB to IIIA -mutated NSCLC. Nevertheless, adapting this approach to include a molecular residual disease (MRD)-guided de-escalation strategy warrants further investigation.
Methods: From January 2019 to December 2022, 71 patients with stages I to III NSCLC and (exon 19 deletion or L858R) mutations were enrolled in this observational study.
Treatment Strategies in Elderly Patients With Operable, Hormone Receptor-negative Breast Cancer.
Cancer Diagn Progn
January 2025
Department of Breast and Endocrine Surgery, Mitsui Memorial Hospital, Tokyo, Japan.
Background/aim: Elderly patients with early-stage breast cancer have potentially been underrepresented in clinical trials. Thus, treatment strategies for a minority of elderly patients with hormone receptor (HR)-negative breast cancer may be inadequately informed.
Patients And Methods: We retrospectively reviewed 126 patients with HR-negative breast cancer aged ≥65 years.
Background: Decisions about stroke prevention strategies in atrial fibrillation (AF) typically balance thromboembolism reduction against increased bleeding from oral anticoagulation therapy (OAC). When determining eligibility for OAC, guidelines recommend calculation of thromboembolic event rates using a validated score such as CHA2DS2-VASc. In contrast, routine calculation of bleeding scores is not recommended, in part because many patient factors associated with an increased risk of bleeding are associated with an even larger increased risk of ischemic stroke.
View Article and Find Full Text PDFPharmacist-led antimicrobial stewardship program in the treatment of bacteraemia in paediatric patients: a multivariate analysis.
Infect Prev Pract
December 2024
Antimicrobial Stewardship Program, Pequeno Príncipe Hospital, Curitiba, PR, Brazil.
Background: Care bundles are a recognised strategy to improve treatment. When managed through an Antimicrobial Stewardship Program (ASP) based on the pharmacist-led program model, care bundles can be an effective tool to guide decision making in clinical practice and to improve patient outcomes. This study aimed to evaluate the results of a pharmacist-led ASP which included a care bundle based on clinical outcomes of bacteraemia (SAB) in a paediatric hospital.
View Article and Find Full Text PDFOutcomes and Trends in Axillary Management of Stage cN3b Breast Cancer Patients.
Ann Surg Oncol
December 2024
Department of Surgery, University of North Carolina, Chapel Hill, NC, USA.
Background: There is limited data regarding sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) for cN3b patients, who present with both axillary and ipsilateral internal mammary node involvement. We examined trends in the use of SLNB in cN3b patients and survival by axillary procedure for those with nodal pathologic complete response (nPCR).
Methods: Adult women with nonmetastatic cN3b invasive breast carcinoma between 2012 and 2021 were selected from the National Cancer Database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!